<DOC>
	<DOC>NCT00673556</DOC>
	<brief_summary>To assess the efficacy and safety of Alefacept compared to placebo for the treatment of Chronic Plaque Psoriasis in patients for whom conventional therapies are ineffective and inappropriate</brief_summary>
	<brief_title>A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate</brief_title>
	<detailed_description>Patients who completed the initial 24-week treatment course (12 weeks of weekly dosing following b y 12 weeks of follow-up) and met the eligibility criteria continued in the 24-week open label extension</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Diagnosis of Chronic Plaque Psoriasis involving ≥ 10% body surface area Treatment history for Psoriasis in which 3 or more conventional antipsoriatic therapies are inappropriate or ineffective CD4+ T lymphocyte counts at or above the lower limit of normal Clinically significant abnormal hematology values or blood chemistry values AST or ALT ≥ 3x the upper limit of normal Other types of Psoriasis Serious infection within the 3 months prior to the first dose of study drug History of drug or alcohol abuse within the past 2 years Antibody positive for HIV History of malignancy History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease Exposure to psoriasismodifying phototherapy or highpotency topical corticosteroid therapy within 2 weeks prior to the first dose of study drug Exposure to systemic antipsoriatic therapy , topical immunomodulators or topical CNIs within 4 weeks prior to the first dose of study drug Current treatment with any therapy for tuberculosis Previous exposure to Alefacept Nursing mothers, pregnant women, and women planning to become pregnant during the study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Alefacept</keyword>
</DOC>